ORIC Pharmaceuticals, Inc.
http://oricpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ORIC Pharmaceuticals, Inc.
Finance Watch: More Good To Come? CG Oncology Grosses $380m In Year’s First IPO
Public Company Edition: CG Oncology grossed $380m in the first biopharma IPO in the US in 2024. Follow-on offerings have been robust recently, with Edgewise and Immatics grossing $240m and $175m, respectively.
Jefferies Conference Highlights How Biotech’s Rollercoaster Ride Will Continue Into 2024
Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.
Newly Unveiled Ampersand's CEO On ‘Programmable’ Medicines And Flagship’s Winning Formula
Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.
Finance Watch: Two Biopharma IPOs Bring US Total To 17
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice